Ronac Mamtani, MD, MSCE

faculty photo
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-308
3400 Civic Center Blvd
Philadelphia, PA 19147
Office: 2156627606
Fax: (215) 349-8551
Education:
BS
Cornell University, 2002.
MD (Internal Medicine)
Stony Brook School of Medicine, 2006.
MS (Clinical Epidemiology)
University of Pennsylvania , 2012.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Parikh RB, Feld EK, Galsky MD, Adamson BJ, Cohen AB, Baxi SS, Boursi SB, Christodouleas JP, Vaughn DJ, Meropol NJ, Mamtani R.: First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis. Future Oncol. Dec 16 2019 Notes: [Epub ahead of print]

Vajravelu RK, Copelovitch L, Osterman MT, Scott FI, Mamtani R, Lewis JD, Denburg MR.: Risk for Chronic Kidney Disease in Patients with Inflammatory Bowel Diseases Increases with Age but is not Associated with 5-aminosalicylate Use. Clin Gastroenterol Hepatol pii: S1542-3565(19): 31245-5, Nov 1 2019.

Corbett CJ, Xia L, Mamtani R, Malkowicz SB, Guzzo TJ.: Survival Benefit Persists With Delayed Initiation of Adjuvant Chemotherapy Following Radical Cystectomy for Locally Advanced Bladder Cancer. Urology 132: 143-149, Oct 2019.

Feld E, Harton J, Meropol NJ, Adamson BJS, Cohen A, Parikh RB, Galsky MD, Narayan V, Christodouleas J, Vaughn DJ, Hubbard RA, Mamtani R.: Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer. Eur Urol. 76(4): 524-532, Oct 2019.

Margalit O, Mamtani R, Lawrence YR, Yang YX, Reiss KA, Golan T, Halpern N, Aderka D, Giantonio B, Shacham-Shmueli E, Boursi B.: Postoperative Radiation for Pathologic Stage T4 Colon Cancers Receiving Adjuvant Chemotherapy. Clin Colorectal Cancer 18(3): 226-230, Sep 2019.

Lai Y, Zhong Y, Li H, Patterson K, Hale O, Meng Y, Frenkl TL, Godwin JL, Mamtani R: Cost-effectiveness of pembrolizumab as first-line treatment of locally advanced or metastatic urothelial carcinoma ineligible for cisplatin-based therapy in the United States. American Society of Clinical Oncology, Quality Care Symposium, San Diego, CA Sep 2019 Notes: "Poster Presentation"

Parikh R, Adamson B, Galsky M, Khozin S, Baxi S, Cohen A, Mamtani R.: Association between FDA label restriction and immunotherapy and chemotherapy use in bladder cancer. JAMA 322(12): 1209-1211, Sep 24 2019.

Margalit O, Mamtani R, Kopetz S, Yang YX, Lawrence YR, Abu-Gazala S, Reiss KA, Golan T, Halpern N, Aderka D, Giantonio B, Shacham-Shmueli E, Boursi B.: Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma. Oncologist 24(8): e671-e676, Aug 2019.

Feld E, Harton J, Meropol NJ, Adamson BJS, Cohen A, Parikh RB, Galsky MD, Narayan V, Christodouleas J, Vaughn DJ, Hubbard RA, Mamtani R: Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer. International Society of Pharmacoepidemiology , Philadelphia, PA Aug 2019 Notes: "Poster Presentation"

Parikh RB, Galsky MD, Gyawali B, Riaz F, Kaufmann TL, Cohen AB, Adamson BJS, Gross CP, Meropol NJ, Mamtani R.: Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real-World Practice. Oncologist. 24(6): e397-e399, Jun 2019.

back to top
Last updated: 01/16/2020
The Trustees of the University of Pennsylvania